DOCSLIB.ORG

Us 2018 / 0305689 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e . MANA sequence Passenger strand (sense strand has sequence identity with a region on the ternplate strand located within + / - 2000 of TSS Patent Application Publication Oct. 25 , 2018 US 2018 / 0305689 A1 Codingstrand Templatestrand F16.1FIG.1 Targettranscript,2.3MRNA wwwSunTargetantisenseRNAtranscript,e.gNAT T55)site(startTranscription Passengerstrand(sense)hassequenceidentitywitharegionon thetemplatestrandlocatedwithin+/-2000ofTSS SORNAJensestrand(Passenger 3'SARNAantisensestrand(Guide) o Targeted Sequence Target Gene US 2018 /0305689 A1 Oct. 25 , 2018 SARNA COMPOSITIONS AND METHODS OF herein by reference in its entirety . Please refer to the end of USE the specification for access instructions. CROSS - REFERENCE TO RELATED FIELD OF THE INVENTION APPLICATIONS [0004 ] The invention relates to oligonucleotides , specifi cally SaRNA , compositions for modulating target gene [ 0001 ] This application is a 35 U . S . C . $ 371 U . S . National expression and to the methods of using the compositions in Stage Entry of International Application No . PCT /GB2016 / diagnostic and therapeutic applications. LENGTHY TABLES The patent application contains a lengthy table section . A copy of the table is available in electronic form from the USPTO web site (http : / / seqdata. uspto . gov / ? pageRequest = docDetail & DocID = US20180305689A1) . An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1 . 19 ( b ) ( 3 ) . 051116 filed Apr. 21 , 2016 , entitled SARNA COMPOSI BACKGROUND OF THE INVENTION TIONS AND METHODS OF USE , which claims the benefit of priority of U . S . Provisional Application No . 62 / 150 ,892 [0005 ] Recently it has been discovered that short RNAs filed Apr. 22 , 2015, entitled SARNA COMPOSITIONS can regulate transcription by destructing transcripts that are AND METHODS OF USE , U . S . Application No. 62 / 150 , sense or antisense to a given mRNA and which are presumed 893 filed Apr. 22 , 2015 , entitled SARNA COMPOSITIONS to be non - coding transcripts . Destruction of the non - coding AND METHODS OF USE , U . S . Application No . 62 / 150 , transcripts which are sense, or identical to , the given mRNA 897 filed Apr. 22 , 2015 , entitled SARNA COMPOSITIONS results in transcriptional repression of that mRNA , whereas AND METHODS OF USE , U . S . Application No. 62 / 150 , destruction of the non -coding transcripts which are antisense 895 filed Apr. 22 , 2015 , entitled SARNA COMPOSITIONS to the given mRNA results in transcriptional activation AND METHODS OF USE , U . S . Application No. 62 / 150 , and / or increased expression of the mRNA or the level of 904 filed Apr. 22 , 2015 , entitled SARNA COMPOSITIONS protein encoded by the mRNA . By targeting such non AND METHODS OF USE , U . S . Application No. 62 / 150 , coding transcripts , short RNAs can therefore be used to 908 filed Apr. 22 , 2015 , entitled SARNA COMPOSITIONS up - regulate specific genes at either the nucleic acid or AND METHODS OF USE and U . S . Application No. protein . Small duplex RNAs have also been discovered to 62/ 150 , 900 filed Apr. 22 , 2015 , entitled SARNA COMPO increase gene expression by targeting ncRNAs that overlap SITIONS AND METHODS OF USE the contents of which gene promoters (Janowski et al ., Nature Chemical Biology , are each incorporated herein by reference in their entirety . vol. 3 : 166 - 173 (2007 ) , the contents of which are incorpo rated herein by reference in their entirety ) . REFERENCE TO SEQUENCE LISTING [0006 ] Any short RNA which leads to up - regulation of the expression of a target gene by any mechanism is termed a [ 0002 ] The instant application contains a " lengthy ” short activating RNA or small activating RNA ( SARNA ) . Sequence Listing which has been submitted via DVD - R in Known methods of up -regulating a target gene by use of lieu of a printed paper copy, and is hereby incorporated by saRNAs can involve the detection of an RNA transcript reference in its entirety . This contains a sequence listing text which is antisense to the target gene of interest and design file as part of the originally filed subject matter as follows: ing short RNA molecules which down -regulate the identified File name: 20581300US371 _ SL . txt; File size : 974 , 266 , 368 transcript. For instance, U . S . Pat. No . 8 , 288 ,354 to Wahl bytes ; Date created : Oct. 19 , 2017 . These DVD - Rs are estedt, the contents of which are incorporated herein by labeled “ CRF, ” “ Copy 1 , ” and “ Copy 2 , ” respectively , and reference in their entirety , discloses a method of modulating each contain only one identical file , as identified immedi expression of a target gene comprising targeting a nucleic ately above . The machine- readable format of each DVD - R acid molecule to a naturally occurring anti - sense transcript is IBM -PC and the operating system of each disc is MS - (NAT ) of a sense strand of the targeted gene in a target cell , Windows. wherein the nucleic acid molecule targeting the NAT is complementary to the NAT. The NAT may be a coding RNA transcript or a non - coding RNA transcript lacking any REFERENCE TO LENGTHY TABLE extensive open reading frame . In another example , WO [ 0003 ] The specification includes a Lengthy Table 1 and a 2012 / 065143 to Krieg et al . , the contents of which are Lengthy Table 2 . Lengthy Table 1 has been submitted via incorporated herein by reference in their entirety, teaches a EFS -Web in electronic format as follows: File name: method of activating expression of a target gene comprising Tablel 1300US371 _ coding . txt, Date created : Oct. 19 , blocking the binding of a long non -coding RNA ( Inc -RNA ) 2017 ; File size : 2 ,916 ,312 bytes and is incorporated herein to Polycomb repressive complex 2 (PRC2 ) protein by a by reference in its entirety . Lengthy Table 2 has been single - stranded oligonucleotide, thereby preventing the Inc submitted via EFS -Web in electronic format as follows: File RNA from suppressing the target gene . name: Table2 _ 1300US371 _ noncoding . txt, Date created : [ 0007 ] There remains, however, a need for compositions Oct. 19 , 2017 ; File size : 802 ,071 bytes and is incorporated and methods for the targeted modulation of genes via US 2018 /0305689 A1 Oct. 25 , 2018 activation with saRNA which do not require the a priori invention means a single - stranded or double - stranded RNA identification of a NAT or rely on interactions at the poly that upregulates or has a positive effect on the expression of comb complex for prophylactic diagnostic and /or therapeu a specific gene . The saRNA may be single - stranded of 14 to tic purposes . 30 nucleotides . The saRNA may also be double - stranded , each strand comprising 14 to 30 nucleotides . The gene is BRIEF DESCRIPTION OF THE DRAWINGS called the target gene of the saRNA . As used herein , the [0008 ] The foregoing and other objects, features and target gene is a double - stranded DNA comprising a coding advantages will be apparent from the following description strand and a template strand . For example , an saRNA that of particular embodiments of the invention , as illustrated in upregulates the expression of the AGGALT2 gene is called the accompanying drawings in which like reference charac an “ A3GALT2 - saRNA ” and the A3GALT2 gene is the target ters refer to the same parts throughout the different views. gene of the A3GALT2 - saRNA . A target gene may be any The drawings are not necessarily to scale , emphasis instead gene of interest. In some embodiments , a target gene has a being placed upon illustrating the principles of various promoter region on the template strand . [0020 ] By " upregulation ” or “ activation ” of a gene is embodiments of the invention . meant an increase in the level of expression of a gene , or [ 0009 ] FIG . 1 is a schematic illustrating the relationships levels of the polypeptide ( s ) encoded by a gene or the activity among the nucleic acid moieties involved in the function of thereof , or levels of the RNA transcript( s ) transcribed from an saRNA of the invention . the template strand of a gene above that observed in the absence of the saRNA of the present invention . The saRNA SUMMARY OF THE INVENTION of the present invention may have a direct upregulating [ 0010 ] The present invention provides compositions, effect on the expression of the target gene .
Recommended publications
  • Supracondylar Femoral Extension Osteotomy and Patellar Tendon Advancement in the Management of Persistent Crouch Gait in Cerebral Palsy

    Supracondylar Femoral Extension Osteotomy and Patellar Tendon Advancement in the Management of Persistent Crouch Gait in Cerebral Palsy

    Original Article Supracondylar femoral extension osteotomy and patellar tendon advancement in the management of persistent crouch gait in cerebral palsy Sakti Prasad Das, Sudhakar Pradhan, Shankar Ganesh1, Pabitra Kumar Sahu, Ram Narayan Mohanty, Sanjay Kumar Das ABSTRACT Background: Severe crouch gait in adolescent cerebral palsy is a difficult problem to manage. The patients develop loading of patellofemoral joint, leading to pain, gait deviation, excessive energy expenditure and progressive loss of function. Patella alta and avulsion of patella are the other complications. Different treatment options have been described in the literature to deal with this difficult problem. We evaluated outcome of supracondylar femoral extension osteotomy (SCFEO) and patellar tendon advancement (PTA) in the treatment of crouch gait in patients with cerebral palsy. Materials and Methods: Fourteen adolescents with crouch gait were operated by SCFEO and PTA. All subjects were evaluated pre and postoperatively. Clinical, radiographic, observational gait analysis and functional measures were included to assess the changes in knee function. Results: Cases were followed up to 3 years. The patients walked with increased knee extension and improvement in quadriceps muscle strength. Knee pain was decreased and improvements in functional mobility and radiologic improvement were found. Conclusion: SCFEO and PTA for adolescent crouch gait is effective in improving knee extensor strength, reducing knee pain and improving function. Key words: Crouch gait, patellar
  • Unresolved, Atraumatic Breast Hematoma: Post-Irradiation Or Secondary Breast Angiosarcoma

    Unresolved, Atraumatic Breast Hematoma: Post-Irradiation Or Secondary Breast Angiosarcoma

    Breast Disease 33 (2011/2012) 139142 139 DOI 10.3233/BD-2012-0331 IOS Press Case Report Unresolved, atraumatic breast hematoma: Post-irradiation or secondary breast angiosarcoma Glenn Hanna, Samuel J. Lin, Michael D. Wertheimer and Ranjna Sharma Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Department of Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Abstract. Post-irradiation or secondary angiosarcoma of the breast was rst described in the 1980s in patients treated with breast conserving therapy for cancer. The primary management of radiation-induced breast angiosarcoma has focused on surgical resection with an emphasis on achieving negative tumor margins. While surgery remains a key component of treatment, novel therapeutic approaches have surfaced. Despite such advances in treatment, prognosis remains poor. Keywords: Breast cancer, breast conservation therapy, secondary angiosarcoma 1. Clinical scenario amination showed the left breast to be larger than the right, with a 10 15cm areaofa clinicalhematomalo- A 64-year-old post-menopausal Caucasian female cated in the superior and inferior outer quadrants. The presented to our institution with a seven month history overlying skin was hemorrhagic, necrotic and had in- of an unresolved left breast hematoma. Of note, she durated features with areas of active bleeding. Initially, had a history of left breast inltrating ductal carcinoma no discrete underlying mass was identied on physical that was Her-2/Neu negative with estrogen and proges- examination. Areas of peau de orange surrounded the terone receptor positivity seven years prior. She had lesion. She had no palpable lymphadenopathy.
  • Implications in Parkinson's Disease

    Implications in Parkinson's Disease

    Journal of Clinical Medicine Review Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease Silvia Paciotti 1,2 , Elisabetta Albi 3 , Lucilla Parnetti 1 and Tommaso Beccari 3,* 1 Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy; [email protected] (S.P.); [email protected] (L.P.) 2 Section of Physiology and Biochemistry, Department of Experimental Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy 3 Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti, 06123 Perugia, Italy; [email protected] * Correspondence: [email protected] Received: 29 January 2020; Accepted: 20 February 2020; Published: 21 February 2020 Abstract: Ceramides are a family of bioactive lipids belonging to the class of sphingolipids. Sphingolipidoses are a group of inherited genetic diseases characterized by the unmetabolized sphingolipids and the consequent reduction of ceramide pool in lysosomes. Sphingolipidoses include several disorders as Sandhoff disease, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, Niemann Pick disease, Farber disease, and GM2 gangliosidosis. In sphingolipidosis, lysosomal lipid storage occurs in both the central nervous system and visceral tissues, and central nervous system pathology is a common hallmark for all of them. Parkinson’s disease, the most common neurodegenerative movement disorder, is characterized by the accumulation and aggregation of misfolded α-synuclein that seem associated to some lysosomal disorders, in particular Gaucher disease. This review provides evidence into the role of ceramide metabolism in the pathophysiology of lysosomes, highlighting the more recent findings on its involvement in Parkinson’s disease. Keywords: ceramide metabolism; Parkinson’s disease; α-synuclein; GBA; GLA; HEX A-B; GALC; ASAH1; SMPD1; ARSA * Correspondence [email protected] 1.
  • Iron Depletion Reduces Abce1 Transcripts While Inducing The

    Iron Depletion Reduces Abce1 Transcripts While Inducing The

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 22 October 2019 doi:10.20944/preprints201910.0252.v1 1 Research Article 2 Iron depletion Reduces Abce1 Transcripts While 3 Inducing the Mitophagy Factors Pink1 and Parkin 4 Jana Key 1,2, Nesli Ece Sen 1, Aleksandar Arsovic 1, Stella Krämer 1, Robert Hülse 1, Suzana 5 Gispert-Sanchez 1 and Georg Auburger 1,* 6 1 Experimental Neurology, Goethe University Medical School, 60590 Frankfurt am Main; 7 2 Faculty of Biosciences, Goethe-University Frankfurt am Main, Germany 8 * Correspondence: [email protected] 9 10 Abstract: Lifespan extension was recently achieved in Caenorhabditis elegans nematodes by 11 mitochondrial stress and mitophagy, triggered via iron depletion. Conversely in man, deficient 12 mitophagy due to Pink1/Parkin mutations triggers iron accumulation in patient brain and limits 13 survival. We now aimed to identify murine fibroblast factors, which adapt their mRNA expression 14 to acute iron manipulation, relate to mitochondrial dysfunction and may influence survival. After 15 iron depletion, expression of the plasma membrane receptor Tfrc with its activator Ireb2, the 16 mitochondrial membrane transporter Abcb10, the heme-release factor Pgrmc1, the heme- 17 degradation enzyme Hmox1, the heme-binding cholesterol metabolizer Cyp46a1, as well as the 18 mitophagy regulators Pink1 and Parkin showed a negative correlation to iron levels. After iron 19 overload, these factors did not change expression. Conversely, a positive correlation of mRNA levels 20 with both conditions of iron availability was observed for the endosomal factors Slc11a2 and Steap2, 21 as well as for the iron-sulfur-cluster (ISC)-containing factors Ppat, Bdh2 and Nthl1.
  • Massachusetts Breastfeeding Resource Guide

    Massachusetts Breastfeeding Resource Guide

    Massachusetts Breastfeeding Resource Guide 2008 Edition © 254 Conant Road Weston, MA 02493 781 893-3553 Fax 781 893-8608 www.massbfc.org Massachusetts Breastfeeding Coalition Leadership Chair Board Member Melissa Bartick, MD, MS Lauren Hanley, MD Treasurer Board Member Gwen MacCaughey Marsha Walker, RN, IBCLC NABA, Lactation Associates Clerk Xena Grossman, RD, MPH Board Member Anne Merewood, MPH, IBCLC Board Member Lucia Jenkins, RN, IBCLC La Leche League of MA RI VT 10th edition (2008) Compiled and edited by Rachel Colchamiro, MPH, RD, LDN, CLC and Jan Peabody Cover artwork courtesy of Peter Kuper Funding for the printing and distribution of the Massachusetts Breastfeeding Resource Guide is provided by the Massachusetts Department of Public Health-Bureau of Family and Community Health, Nutrition Division. Permission is granted to photocopy this guide except for the three reprinted articles from the American Academy of Pediatrics and two articles from the American Academy of Family Physicians. Adapted from the Philadelphia Breastfeeding Resource Handbook. hhhhhhhhhhhhhhhhhhhhTable of Contents Organizational statements on breastfeeding…………………………………………………………….2 Breastfeeding and the Use of Human Milk, American Academy of Pediatrics…………………….6 Breastfeeding Position Paper, American Academy of Family Physicians……………………...…19 Breastfeeding initiatives………………………...……………………………………………………...…37 Breastfeeding support and services…………………………………………...………………...…....…39 La Leche League International leaders………….…………………………………………………...….40 Lactation consultants………………………………………………………………………………….…..44
  • Primary Liver Cancer: Epidemiological And

    Primary Liver Cancer: Epidemiological And

    PRIMARY LIVER CANCER: EPIDEMIOLOGICAL AND BIOMARKER DISCOVERY STUDIES Nimzing Gwamzhi Ladep Imperial College London Department of Medicine December 2013 Thesis submitted for Doctor of Philosophy 1 THESIS ABSTRACT With previous reports indicating changes in mortality, risk factors and management of primary liver cancer (PLC), evaluation of current trends in the incidence and mortality rates was indicated. Late diagnosis has been implicated to be a major contributor to the high fatality rates of PLC. This work aimed at: studying trends of PLC by subcategories globally in general, and in England and Wales, in particular; investigating liver-related morbidities of HIV infected patients in an African setting; and discovering urinary biomarkers of hepatocellular carcinoma. The World Health Organisation (WHO) and Small Area Health Statistics Unit (SAHSU) databases were interrogated respectively, in order to achieve the first aim. The second aim was achieved through utilisation of databases of an African-based HIV treatment programme- AIDS Prevention Initiative in Nigeria (APIN), located in Jos, Nigeria. The European Union-funded Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) case-control study in three West African countries was the platform through which urinary metabolic profiling was accomplished. Proton nuclear magnetic resonance spectroscopy (NMR) and parallel ultra-performance liquid chromatography mass spectrometry (UPLC-MS) were used for biomarker discovery studies. Mortality rates of intrahepatic bile duct carcinoma (IHBD) increased in all countries that were studied. Misclassification of hilar cholangiocarcinoma accounted for only a small increase in the rate of IHBD in England and Wales. With over 90% screening rate for viral hepatitides, the rates of hepatitis B (HBV), hepatitis C (HCV) and 2 HBV/HCV in HIV-infected patients in the APIN programme were 17.8%, 11.3% and 2.5% respectively.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2

    Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2

    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
  • Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency

    Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency

    Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency By Fabian Yu A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by Fabian PS Yu 2018 Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency Fabian Yu Doctor of Philosophy Institute of Medical Science University of Toronto 2018 Abstract Farber disease (FD) is a devastating Lysosomal Storage Disorder (LSD) caused by mutations in ASAH1, resulting in acid ceramidase (ACDase) deficiency. ACDase deficiency manifests along a broad spectrum but in its classical form patients die during early childhood. Due to the scarcity of cases FD has largely been understudied. To circumvent this, our lab previously generated a mouse model that recapitulates FD. In some case reports, patients have shown signs of visceral involvement, retinopathy and respiratory distress that may lead to death. Beyond superficial descriptions in case reports, there have been no in-depth studies performed to address these conditions. To improve the understanding of FD and gain insights for evaluating future therapies, we performed comprehensive studies on the ACDase deficient mouse. In the visual system, we reported presence of progressive uveitis. Further tests revealed cellular infiltration, lipid buildup and extensive retinal pathology. Mice developed retinal dysplasia, impaired retinal response and decreased visual acuity. Within the pulmonary system, lung function tests revealed a decrease in lung compliance. Mice developed chronic lung injury that was contributed by cellular recruitment, and vascular leakage. Additionally, we report impairment to lipid homeostasis in the lungs. ii To understand the liver involvement in FD, we characterized the pathology and performed transcriptome analysis to identify gene and pathway changes.
  • Appendix Cancer and Pseudomyxoma Peritonei (PMP) a Guide for People Affected by Cancer

    Appendix Cancer and Pseudomyxoma Peritonei (PMP) a Guide for People Affected by Cancer

    Cancer information fact sheet Understanding Appendix Cancer and Pseudomyxoma Peritonei (PMP) A guide for people affected by cancer This fact sheet has been prepared What is appendix cancer? to help you understand more about Appendix cancer occurs when cells in the appendix appendix cancer and pseudomyxoma become abnormal and keep growing and form a peritonei (PMP). mass or lump called a tumour. Many people look for support after The type of cancer is defined by the particular being diagnosed with a cancer that cells that are affected and can be benign (non- is rare or less common than other cancerous) or malignant (cancerous). Malignant cancer types. This fact sheet includes tumours have the potential to spread to other information about how these cancers parts of the body through the blood stream or are diagnosed and treated, as well as lymph vessels and form another tumour at a where to go for additional information new site. This new tumour is known as secondary and support services. cancer or metastasis. Many people feel shocked and upset when told they have cancer. You may experience strong emotions The abdomen after a cancer diagnosis, especially if your cancer is rare or less common like appendix cancer or PMP. A feeling of being alone is usual with rare cancers, and you might be worried about how much is known about your type of cancer as well as how it will be managed. You may also be concerned about the cancer coming back after treatment. Linking into local support services (see last page) can help overcome feelings of isolation and will give you information that you may find useful.
  • Investigation of Candidate Genes and Mechanisms Underlying Obesity

    Investigation of Candidate Genes and Mechanisms Underlying Obesity

    Prashanth et al. BMC Endocrine Disorders (2021) 21:80 https://doi.org/10.1186/s12902-021-00718-5 RESEARCH ARTICLE Open Access Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules G. Prashanth1 , Basavaraj Vastrad2 , Anandkumar Tengli3 , Chanabasayya Vastrad4* and Iranna Kotturshetti5 Abstract Background: Obesity associated type 2 diabetes mellitus is a metabolic disorder ; however, the etiology of obesity associated type 2 diabetes mellitus remains largely unknown. There is an urgent need to further broaden the understanding of the molecular mechanism associated in obesity associated type 2 diabetes mellitus. Methods: To screen the differentially expressed genes (DEGs) that might play essential roles in obesity associated type 2 diabetes mellitus, the publicly available expression profiling by high throughput sequencing data (GSE143319) was downloaded and screened for DEGs. Then, Gene Ontology (GO) and REACTOME pathway enrichment analysis were performed. The protein - protein interaction network, miRNA - target genes regulatory network and TF-target gene regulatory network were constructed and analyzed for identification of hub and target genes. The hub genes were validated by receiver operating characteristic (ROC) curve analysis and RT- PCR analysis. Finally, a molecular docking study was performed on over expressed proteins to predict the target small drug molecules. Results: A total of 820 DEGs were identified between